Regeneron's CIDEB siRNA Shows Early Promise in MASLD, Adds Incremental Pipeline Optionality

What happened

Regeneron presented positive early data for its CIDEB siRNA in MASLD at AASLD, showing up to 80% liver fat reduction sustained through 36 weeks with a single dose. This data adds a potential new program to Regeneron's pipeline, but it is early-stage and was not a focal point in the latest DeepValue master report, which centers on the EYLEA franchise transition and Dupixent profit-share. The company's core investment thesis remains tied to near-term catalysts: EYLEA HD physician demand trends and the expected Q2 2026 FDA decision on the pre-filled syringe, which can stabilize retina economics. While CIDEB siRNA could become part of a post-EYLEA growth stack, it does not alter the current risk/reward setup, as the stock trades at 17.7x P/E with a POTENTIAL BUY rating and attractive entry around $720. Investors should view this as a positive but minor pipeline readout that supports long-term optionality without changing the near-term equity narrative.

Implication

Over the next 6-12 months, the primary value driver is whether EYLEA HD can offset EYLEA 2mg erosion and the pre-filled syringe approval can improve adoption. The CIDEB siRNA data, while promising, is too early to contribute to revenue and does not alleviate the concentration risk from EYLEA and Sanofi collaboration. If the EYLEA transition falters, the balance sheet will protect solvency but not valuation, and pipeline assets like CIDEB siRNA would need to mature significantly to shift the narrative. Therefore, maintain the existing thesis with a potential buy on weakness near $720, and only upgrade conviction if EYLEA HD demand trends improve and PFS approval is secured, or if additional late-stage pipeline readouts materially de-risk the post-EYLEA growth story. The CIDEB data adds a small positive but does not change the probabilities in the base, bear, or bull scenarios.

Thesis delta

The CIDEB siRNA data introduces a new early-stage asset that could strengthen the long-term pipeline argument, but it does not alter the current investment thesis, which is driven by near-term EYLEA HD execution and Dupixent earnings support. No change to rating or price targets at this time.